Cara Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Janney Cuts Price Target on Cara Therapeutics (CARA) as UP is Delayed
March 11, 2016 10:12 AM ESTJanney Capital maintained a Buy rating on Cara Therapeutics (NASDAQ: CARA), and cut the price target to $18.00 (from $23.00), following the company's 4Q earnings report and conference call. The most significant development on the call was the disclosure that its December 2015 meeting with the FDA regarding its effort to develop CR845 for UP. Janney thought... More
